Entity Addresses, Address Type [Axis] Business Contact [Member] Components of equity [axis] Issued capital [member] Capital reserve [member] Warrant reserve [member] Reserve of share-based payments [member] Translation reserve Retained earnings [member] Equity attributable to owners of parent [member] Non-controlling interests [member] Counterparties [axis] Advance Cancer Centre Pte Ltd [member] CytoMed Therapeutics (Malaysia) Sdn Bhd [member] LongevityBank Pte Ltd [member] IPSC Depository Sdn Bhd [member] Puricell Lab Pte Ltd [member] Classes of property, plant and equipment [axis] Intellectual properties licenses [member] Computer software licenses [member] Buildings [member] Property, plant and equipment by operating lease status [axis] Property, plant and equipment subject to operating leases [member] Range [axis] Bottom of range [member] Top of range [member] Laboratory equipment [member] Motor vehicle [member] Furniture and fittings equipment [member] Renovation [member] Categories of related parties [axis] Third party [member] Associates [axis] Total for all associates [member] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Gross carrying amount [member] Freehold land [member] Motor vehicles [member] Fixtures and fittings [member] Right-of-use assets [member] Accumulated depreciation [member] Freehold land and building [member] Classes of intangible assets other than goodwill [axis] Computer software [member] Customer-related intangible assets [member] Licences and franchises [member] Technology-based intangible assets [member] Technical [member] Maturity [axis] Later than one years and not later than five years [member] Later than five years and not later than ten years [member] Later than ten years [member] Classes of financial instruments [axis] Bank loan [member] Later than one month and not later than six months [member] 6 – 12 months [member] Later than one year and not later than five years [member] Classes of share capital [axis] Ordinary shares [member] Initial public offering [member] Types of contracts [axis] Underwriting agreements [member] Types of antidilutive instruments [axis] Warrants [member] Levels of fair value hierarchy [axis] Level 2 of fair value hierarchy [member] Additional paid-in capital [member] 2023 Equity incentive plan [member] At-the-market [member] Defined benefit plans [axis] 2023 Equity Incentive Plan [Member] Measurement [axis] Overtime [member] At A Point In Time [member] Products and services [axis] Hiring incentive and training programme [member] Market readiness assistance grant [member] BeST 2.0 [member] Others [member] Contract duration [axis] Licencing agreement [member] Not later than one year [member] Later than five years [member] Classes of financial assets [axis] Financial assets at amortised cost, class [member] Financial assets at FVOCI [member] Classes of financial liabilities [axis] Financial liabilities at amortised cost, class [member] Categories of financial liabilities [axis] Financial liabilities at fair value through profit or loss, category [member] Currency [Axis] Singapore, Dollars Financial asset [member] Malaysia, Ringgits United States of America, Dollars Financials liabilities [member] Currency in which information is displayed [axis] USD against SGD [member] ATM Sales Agreement [Member] Performance obligations [axis] Strengthened [member] weakened [member] Later than one year and not later than two years [member] Later than two years and not later than five years [member] Total undiscounted cash flow [member] Level 1 of fair value hierarchy [member] Level 3 of fair value hierarchy [member] Debt to equity ratio [member] Geographical [Axis] MALAYSIA SINGAPORE Segments [axis] Immune cell therapy [member] CBU service & related therapy [member] Reportable segments [member] Liabilities arising from financing activities [axis] Warrant liabilities [member] Lease liabilities [member] Third party loan [member] Convertible loan [member] Classes of liabilities [axis] Bank borrowings [member] Total for all related parties [member] Separate management entities [axis] Salaries and Bonus [member] Directors Fees [member] Defined contribution plans [member] Other short term benefits [member] Share based compensation [member] Directors [member] Other key management personnel [member] Non-adjusting events after reporting period [axis] Nonadjusting Event [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Contact Personnel Name Contact Personnel Email Address ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of financial position [abstract] ASSETS Current assets Trade and other receivables Cash and bank balances Total current assets Non-current assets Trade and other receivables Investment in an associate Property, plant and equipment Intangible assets Financial assets, at FVOCI Total non-current assets Total assets LIABILITIES AND EQUITY Current liabilities Trade and other payables Contract liabilities Borrowings Lease liabilities Warrant liabilities Total current liabilities Non-current liabilities Borrowings Lease liabilities Total non-current liabilities Total liabilities Capital and reserves Share capital Capital reserve Share-based payment reserve Translation reserve Accumulated losses Equity attributable to owners of the equity Non-controlling interests Total equity Total liabilities and equity Profit or loss [abstract] Revenue Other operating income Other (losses)/gains including fair value changes on financial instruments - net Lab consumables and cord-blood banking expenses Research expenses Depreciation of property, plant and equipment Amortization of intangible assets Employee benefits expenses Finance expenses Other expenses Share of results of associate Loss before income tax Income tax expense Loss for the year Other comprehensive (loss)/income: Foreign currency translation (loss)/gain Total comprehensive loss for the year Loss attributable to: Equity holders of the Company Non-controlling interests Total Total comprehensive loss attributable to: Equity holders of the Company Non-controlling interests Total Loss per share attributable to equity holders of the Company: Basic Diluted Weighted average number of ordinary shares used in computing loss per share Basic Diluted Statement of changes in equity [table] Statement of changes in equity [line items] Balance Total comprehensive loss for the year Transactions with owners of the Company recognized directly in equity Warrant exercised before year end Issuance of shares Total transactions with owners of the Company Effect of dilution of interest in subsidiaries Warrant reserve capitalized in the year Share-based payment Balance Statement of cash flows [abstract] Operating activities Loss before income tax Adjustments for: Amortization of intangible assets Depreciation of property, plant and equipment Fair value losses on convertible loans Share of results of associate Gain on disposal of associate Share-based payment Fair value on warrant liabilities at inception date Fair value changes on warrant liabilities Written off of intangible asset Interest expense Interest income Written off of property, plant and equipment Unrealized currency translation (gains)/losses Operating cash flows before movements in working capital Trade and other receivables Contract liabilities Trade and other payables Cash used in operations Income tax paid Interest received Net cash used in operating activities Investing activities Proceeds from dilution of interest in a subsidiary Loan to a third party - net Loan to a related party - net Fixed deposits with maturities over 3 months Purchase of property, plant and equipment Purchase of intangible assets Proceed from disposal of associate Fair value through other comprehensive income investment Interest received Net cash (used in)/generated from investing activities Financing activities Proceeds from issuance of ordinary shares Principal payment of third party loan Principal payment of bank borrowings Principal payment of lease liabilities Interest paid Net cash generated from/(used in) financing activities Net increase/(decrease) in cash and cash equivalents Cash and cash equivalents at beginning of year Effects of foreign currency translation on cash and cash equivalents Cash and cash equivalents at end of year Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Type [Axis] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Trading Arrangements, by Individual [Table] Trading Arrangement [Axis] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Material Cybersecurity Incident [Abstract] Material Cybersecurity Incident Nature [Text Block] Material Cybersecurity Incident Scope [Text Block] Material Cybersecurity Incident Timing [Text Block] Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block] Material Cybersecurity Incident Information Not Available or Undetermined [Text Block] General GENERAL Material Accounting Policy Information MATERIAL ACCOUNTING POLICY INFORMATION Notes and other explanatory information [abstract] CASH AND BANK BALANCES TRADE AND OTHER RECEIVABLES INVESTMENT IN AN ASSOCIATE Disclosure of detailed information about property, plant and equipment [abstract] PROPERTY, PLANT AND EQUIPMENT Disclosure of detailed information about intangible assets [abstract] INTANGIBLE ASSETS Disclosure of financial instruments [text block] FINANCIAL ASSETS, AT FVOCI TRADE AND OTHER PAYABLES Contract Liabilities CONTRACT LIABILITIES BORROWINGS LEASE LIABILITIES Warrant Liabilities And Warrant Reserve WARRANT LIABILITIES AND WARRANT RESERVE Disclosure of share capital, reserves and other equity interest [text block] SHARE CAPITAL Capital Reserve CAPITAL RESERVE SHARE-BASED PAYMENT RESERVE REVENUE OTHER OPERATING INCOME Other Lossesgains Including Fair Value Changes On Financial Instruments - Net OTHER (LOSSES)/GAINS INCLUDING FAIR VALUE CHANGES ON FINANCIAL INSTRUMENTS - NET RESEARCH EXPENSES EMPLOYEE BENEFITS EXPENSES FINANCE EXPENSES OTHER EXPENSES INCOME TAX EXPENSE COMMITMENTS FINANCIAL INSTRUMENTS, FINANCIAL RISKS AND CAPITAL RISKS MANAGEMENT SEGMENT INFORMATION Disclosure of cash flow statement [text block] RECONCILIATIONS OF LIABILITIES ARISING FROM FINANCING ACTIVITIES SIGNIFICANT RELATED PARTY TRANSACTIONS Holding Company And Related Company Transactions HOLDING COMPANY AND RELATED COMPANY TRANSACTIONS EVENTS OCCURRING AFTER BALANCE SHEET DATE BASIS OF PREPARATION Adoption of new and revised standards New and revised standards in issued but not yet effective BASIS OF ACCOUNTING BASIS OF CONSOLIDATION CONVENIENCE TRANSLATION FINANCIAL ASSETS FINANCIAL LIABILITIES AND EQUITY INSTRUMENTS INVESTMENT IN AN ASSOCIATE PROPERTY, PLANT AND EQUIPMENT INTANGIBLE ASSETS IMPAIRMENT OF NON-FINANCIAL ASSETS TRADE AND OTHER PAYABLES BORROWINGS LEASES PROVISIONS REVENUE RECOGNITION RESEARCH EXPENSES GOVERNMENT GRANTS SEGMENT REPORTING SHARE CAPITAL INCOME TAX FOREIGN CURRENCY TRANSACTIONS CASH AND BANK BALANCES RELATED PARTIES RESERVES CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY SCHEDULE OF PRINCIPAL ACTIVITIES OF SUBSIDIARIES SCHEDULE OF FINANCIAL INFORMATION OF NON-CONTROLLING INTERESTS SCHEDULE OF PROPERTY PLANT AND EQUIPMENT ESTIMATED USEFUL LIVES SCHEDULE OF CASH AND CASH EQUIVALENTS SCHEDULE OF TRADE AND OTHER RECEIVABLES SCHEDULE OF INVESTMENT IN ASSOCIATE SCHEDULE OF KEY ASSUMPTIONS OF INVESTMENT IN ASSOCIATE SCHEDULE OF FINANCIAL INFORMATION INVESTMENT IN ASSOCIATE SCHEDULE OF RECONCILIATION OF FINANCIAL INFORMATION IN INVESTMENT SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF DEPRECIATION EXPENSE SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF DETAILED INFORMATION ABOUT INTANGIBLE ASSETS SCHEDULE OF AMORTIZATION EXPENSE SCHEDULE OF FINANCIAL ASSETS SCHEDULE OF TRADE AND OTHER PAYABLES SCHEDULE OF CONTRACT LIABILITIES SCHEDULE OF UNSATISFIED PERFORMANCE OBLIGATIONS SCHEDULE OF BORROWINGS SCHEDULE OF BORROWING OF THE GROUP TO INTEREST RATE CHANGES AND CONTRACTUAL REPAYMENT DATES SCHEDULE OF LEASE LIABILITIES SCHEDULE OF CONSOLIDATED STATEMENT OF FINANCIAL POSITIONS SCHEDULE OF WARRANT LIABILITIES SCHEDULE OF FAIR VALUE OF WARRANTS SCHEDULE OF WARRANT RESERVE Disclosure of terms and conditions of share-based payment arrangement [abstract] SCHEDULE OF SHARE CAPITAL SCHEDULE OF SHARE-BASED PAYMENT RESERVE SCHEDULE OF DISAGGREGATION OF REVENUE FROM CONTRACTS WITH CUSTOMERS SCHEDULE OF OTHER OPERATING INCOME SCHEDULE OF OTHER (LOSSES)/GAINS - NET SCHEDULE OF RESEARCH EXPENSES SCHEDULE OF EMPLOYEE BENEFITS EXPENSES SCHEDULE OF FINANCE EXPENSES SCHEDULE OF OTHER EXPENSES SCHEDULE OF CURRENT INCOME TAX EXPENSES SCHEDULE OF INCOME TAX EXPENSES SCHEDULE OF UNUTILIZED TAX LOSSES SCHEDULE OF OPERATING LEASE COMMITMENTS SCHEDULE OF CAPITAL COMMITMENTS SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELLABLE SCHEDULE OF FINANCIAL INSTRUMENTS SCHEDULE OF CURRENCY EXPOSURE BASED ON THE INFORMATION SCHEDULE OF NET FINANCIAL LIABILITY ASSET CURRENCY RISK SCHEDULE OF REMAINING CONTRACTUAL MATURITIES SCHEDULE OF EACH CLASS OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE SCHEDULE OF CAPITAL BASED ON DEBT-TO-EQUITY RATIO SCHEDULE OF GEOGRAPHICAL INFORMATION IN NON-CURRENT ASSETS SCHEDULE OF BUSINESS SEGMENT SCHEDULE OF RECONCILIATIONS OF LIABILITIES ARISING FROM FINANCING ACTIVITIES SCHEDULE OF RELATED PARTY TRANSACTIONS SCHEDULE OF REMUNERATION OF DIRECTORS AND KEY MANAGEMENT PERSONNEL Disclosure of offsetting of financial assets [table] IfrsStatementLineItems [Line Items] Name of entity Principal activities Country of business / incorporation Ownership percentage Loss before tax Income tax expenses Loss after tax Loss allocated to NCI Other comprehensive gain allocated to NCI Total comprehensive loss allocated to NCI Cash flows generated from operating activities Cash flows used in investing activities Cash flows generated from financing activities Current assets Non-current assets Current liabilities Non-current liabilities Net (liabilities)/assets Accumulated NCI Less: fair value adjustments Adjusted accumulated NCI Cash consideration Description of diluted equity interest percentage Number of shares issued Issued capital, amount Disclosure of detailed information about property, plant and equipment [table] Estimated useful lives Convenience translation description Voting rights percent Intangible assets, estimated useful lives Increase decrease in warrant liability Cash at banks Cash on hand Short-term fixed deposits Cash and cash equivalents Less: Fixed deposits with maturities over 3 months Cash and cash equivalents on consolidated statements of cash flows DisclosureOfCashAndBankBalanceTable [Table] DisclosureOfCashAndBankBalanceLineItem [Line Items] Fixed deposit term Effective interest rate percentage Non-Current Other receivables Current Trade receivables Prepayments Prepaid consumables Goods and services tax receivable Sundry deposits Other receivables Interest receivables Total Beginning of financial year Share of post-acquisition profit/(losses) Disposal Currency realignment End of financial year Disclosure of transactions between related parties [table] Loan amount Loan maturity Loan interest rate Revenue growth rate Discount rate Name of entity Principal activities Country of business / incorporation Group's effective equity interest held rate Disclosure of associates [table] Non-current assets (including fair value of hospital license) Current liabilities Non-current liabilities Adjusted net assets of the associate Profit for the year Adjusted net assets Group's equity interest Group share of net assets Carrying value Impairment loss Cash consideration Gain on disposal of profit or loss Disclosure of reconciliation of changes in goodwill [table] Property, plant and equipment, beginning Addition Currency realignment Written off Property, plant and equipment, ending Depreciation of property, plant and equipment (per above) “Research expenses” (Note 21) Total Right of use assets Property, plant and equipment, acquisition Carrying amount of property pledged for bank borrowings Goodwill Intellectual properties licenses (Note (a)) Computer software licenses (Note (b)) Acquired customer relationship (Note (c)) Acquired private blood bank license (Note (d)) Acquired technical disclosure (Note (e)) Total At beginning of financial year Written off Written off At end of financial year Amortization charge Currency realignment Currency realignment Disclosure of detailed information about intangible assets [table] Total “Research expenses” (Note 21)  Amortization expense At beginning of financial year Additions At end of financial year Trade payable Other payables Accrued operating expenses Deferred income Sales and services tax payable Total Schedule Of Contract Liabilities Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table] Partially and fully unsatisfied performance obligations Bank loan, current Bank loan, non-current Total Total At beginning of year Addition in the year Currency realignment Interest charged (Note 23) Payment made At end of year Current Non-current Total Disclosure of detailed information about financial instruments [table] Principal amount Fixed interest rate Installments Depreciation lease liability Cash flow for leases Schedule Of Warrant Liabilities Beginning of financial year, Number of Warrants Beginning of financial year, Amount Beginning of financial year, Weighted Average Exercise Price Fair value changes to profit or loss, Number of Warrants Fair value changes to profit or loss, Amount Fair value changes to profit or loss, Weighted Average Exercise Price Currency realignment, Number of Warrants Currency realignment, Amount Currency realignment, Weighted Average Exercise Price End of financial year, Number of Warrants End of financial year, Amount End of financial year, Weighted Average Exercise Price Disclosure of fair value measurement of assets [table] Expected volatility Risk-free interest rate Expected term (years) Exercise price Spot price Fair value of warrant Schedule Of Warrant Reserve At beginning of year Warrant reserve capitalized in the year At end of year No par value per share Par value per share Shares offering percent Exercise price Expire period Warrant reserve amount At beginning of financial year Warrant exercised Issuance of ordinary shares At end of financial year Issuance of ordinary shares Capitalization of share-based payment reserve Issuance of ordinary shares from the exercise of warrants Disclosure of classes of share capital [table] Warrants Aggregate value Aggregate gross proceeds Offering expenses At beginning of financial year Share-based payment to advisors Share-based payment to employees (Note 22) Currency realignment Share issued and capitalized in the year At end of financial year Total Disclosure of disaggregation of revenue from contracts with customers [table] Government grants Research income Interest income Rental income Others Total Ordinary shares par value Schedule Of Other Lossesgains - Net Fair value losses on convertible loans Foreign currency exchange (loss)/gain - net Written off of intangible asset Written off of property, plant and equipment Gain on disposal of investment in an associate Fair value on warrant liabilities at inception date (Note 14) Fair value changes on warrant liabilities (Note 14) Total Employee benefits expenses (Note 22) Depreciation of property, plant and equipment (Note 7) Amortization of intangible assets (Note 8) Clinical trial expenses Consumables expenses Royalty expenses Professional fees Utilities Others Total Salaries and bonus Directors’ fees Defined contribution plans Share-based compensation Other short-term benefits Total “Research expenses” (Note 21) Total Bank borrowings Third party loan Convertible loans Lease liabilities (Note 13) Total Advertising Annual listing fee Company insurance Entertainment Investor relations expenses Legal fees Low-value assets rental Offering expenses Professional fees Property tax Printing and stationery IT expenses Repair and maintenance Reversal of grant Service fees Share-based payment expenses Subscription fee Transportation and travelling expenses Tools and supplies Utilities Others Total Current tax liability Loss before income tax Tax calculated at tax rate of 17% - different tax rates in other countries - deferred tax assets not recognized - expenses not deductible for tax purposes - income not subject to tax - timing differences arising from revenue recognition - under provision of prior year tax Income tax expenses Tax rate Unutilized tax losses, At beginning of year Addition (Over)/Under-provision in respect of prior years Unutilized tax losses, At end of year Unabsorbed capital allowance, At beginning of year Addition (Over)/Under-provision in respect of prior years Unabsorbed capital allowance, At end of year Total Unrecorded approximate deferred tax benefits @ 17% Unrecorded approximate deferred tax benefits percentage Low value leases Purchase of a property in Malaysia Loan to a third party Total Disclosure of financial liabilities [table] Trade and other receivables Cash and bank balances Financial assets at amortized cost Financial assets at FVOCI Trade and other payables Lease liabilities Borrowing Financial liabilities at amortized cost Financial liabilities at FVTPL NotesAndOtherExplanatoryInformationTable [Table] Unquoted equity instruments Financial assets Trade and other payables Lease liabilities Borrowings Warrant liabilities Financial liabilities Net financial assets Add: Net financial assets denominated respective entities’ functional currencies Currency exposure of financial assets, net of those denominated in the Company’s functional currency Unused tax losses Unabsorbed capital allowance Tax losses with no expiry Disclosure of performance obligations [table] Increase/(decrease) Loss after tax Borrowings (excluding lease liabilities) Warrant liabilities Total equity Debt-to-equity ratio Total Private blood banking expenses Operating results Non-current assets Total assets Non-current liabilities Total liabilities Disclosure of detailed information about borrowings [table] Currency risk rate Bank loan Increase decrease in loan Aggregate offering price Sale of stock, shares Negative cash flow from operating activities Negative working capital Cash and cash equivalents Disclosure of reconciliation of liabilities arising from financing activities [table] Liabilities arising from financing activities at beginning of period Proceeds from borrowings, classified as financing activities Payments Interest expense on borrowings Capitalization of new lease Conversion of ordinary shares Fair value changes Liabilities arising from financing activities at end of period Disclosure of fair value measurement of liabilities [table] Foreign exchange gain (loss) Warrant reserve to share capital Research income Proceeds from sale of equity investment Purchase consideration for acquisition of equity investment Loan receivable Trade receivable from associate Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table] Total Disclosure of materials accounting policy information explanatory. Description of accounting policy for basis of preparation of financial statements explanatory. Description of accounting policy for adoption of new and amended standards and interpretations explanatory. The disclosure of detailed information about financial assets. Description of accounting policy for new standards amendments and interpretations issued but not yet effective explanatory. Description of accounting policy for basis of accounting explanatory. Description of accounting policy for basis of consolidation explanatory. Description of accounting policy for convenience translation explanatory. Disclosure of trade and other payables details explanatory. Accrued expenses. Disclosure of property plant and equipment estimated useful life explanatory. Laboratory equipment [member] Motor vehicle [member] Furniture and fittings equipment [member] Renovation [member] Intellectual properties licenses [member] Computer software licenses [member] Depreciation research and development expenses. Amortization of intangible asset research and development expenses. Clinical trial expenses. Consumables expense. Employee benefits under research expenses. Disclosure of detailed information about employee benefits expenses explanatory. Disclosure of detailed information about research and development expenses explanatory. Interest expense on related party loan. Interest Expense on Third Party Loan. Disclosure of detailed information about other expenses explanatory. Annual Listing Fee. Entertainment expense. Investor relationship expenses. Legal fees expenses. Offering expenses. Other Professional fees. Printing and stationery expense. Information technology expense. Reversal of grant. Subscription expense. Disclosure of detailed information about contract liabilities. Other expense. Tools and supplies. Utilities research expenses. Disclosure of detailed information about finance income expense explanatory. The disclosure of contract liabilities. The disclosure of detailed information about current income tax expenses. The disclosure of detailed information about income tax expenses. Tax effect of deferred tax assets not recognized. Under provision of prior year tax. Amortization of intangible asset. Unabsorbed capital allowance. Description of accounting policy for related parties explanatory. Tax losses with no expiry. Disclosure of unutilized tax losses explanatory. Addition to unused tax losses. Overprovision in respect of prior years unutilized tax losses. Unabsorbed tax losses for capital allowance. Addition to unabsorbed capital allowance. Overprovision in respect of prior years unabsorbed capital allowance. Unutilized tax losses and unabsorbed capital allowance net Description of accounting policy for reserves explanatory. Disclosure of cash and cash equivalent explanatory. Operating lease commitments. Disclosure of detailed information about capital commitments explanatory. Loan to third party. Licencing agreement [member] Bank loan [member] Monthly installments. Disclosure of detailed information about interest rate changes and contractual repayment dates. Financial liabilities at FVTPL . Net financial assets liabilities denominated respective entities functional currencies. Currency exposure of financial assets net of those denominated in companys functional currency. Disclosure of detailed information about operating lease liabilities. Disclosure of detailed information about operating lease commitments explanatory. Addition on lease liabilities. Currency realignment on lease liabilities. Payment of lease liabilities classified as financing activities. Disclosure of net financial liability asset currency risk explanatory. USD against SGD [member] Disclosure of detailed information abouts statement of financial position explanatory. MYR againstSGD [member] Strengthened [member] weakened [member] Negative cash flow from operating activities. Negative working capital. Cash and cash equivalents before fixed deposit maturity adjustment. Debt to equity ratio [member] Debt-to-equity ratio. Disclosure warrant liabilities and warrant reserve explanatory. Immune cell therapy [member] CBU service & related therapy [member] Disclosure of warrant liabilities explanatory. Lab consumables and private blood banking expenses. Number of warrants outstanding. Fair value changes to number of warrants. Currency realignment number of warrants. Fair value changes to profit or loss. Borrowings currency realignment. Capitalization of new leases during year. Increase decrease conversion of convertible units. Weighted average exercise price of share options exercisable in fair value changes to profit or loss. Weighted average exercise price of share options exercisable in currency realignment. Warrant liabilities [member] Third party loan [member] Convertible loan [member] Disclosure of reconciliations of liabilities arising from financing activities explanatory. Initial public offering [member] Underwriting agreements [member] No par value per share. Shares offering percentage. Warrants expiration period. Bank borrowings [member] Increase decrease through warrant reserve capitalized. Fixed deposit Loan to an immediate family of key management personnel. Fixed deposit term Effective interest rate percentage Salaries and Bonus [member] Directors Fees [member] Share Based Payment [member] Disclosure of holding company and related company transactions explanatory. Total undiscounted cash flow [member] Sundry deposits. Expected term (years). Exercise price share spot price. Fair value of warrant. Disclosure warrant reserve explanatory. Third party [member] Warrant exercised. Issuance of ordinary shares Issuance of ordinary shares from the exercise of warrants. Warrant reserve capitalised. Disclosure of investment in associate explanatory. Investments in subsidiaries joint ventures and associates currency realignment. Percentage of discount rate. Loss before income tax Adjustments for unrealized currency translation gains losses Adjustments for fair value loss gain on convertible loans. Disclosure of summarized financial information of material associates explanatory. Noncurrent assets including fair value of hospital license. Disclosure of reconciliation of financial information in investment explanatory. 2023 Equity incentive plan [member] Group share of net assets. Changes on warrant expenses or reserve. Proceeds from non controlling interests of subsidiary. At-the-market [member] Freehold land [member] Payment to fair value through other comprehensive income investment. Accumulated depreciation [member] Freehold land and building [member] Disclosure of capital reserve explanatory. Depreciation under research expenses. The entire disclosure for detailed information about share-based payment arrangements. The amount of written off to investment property other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Investment property] Translation differences. Share issued and capitalized. Disclosure of detailed information about other operating income explanatory. BeST 2.0 [member] Research income. Disclosure of other gain loss net explanatory Disclosure of detailed information about other gain loss net explanatory. Fair value (loss)/gain on convertible loans. Fair value on warrants liabilities at inception date. Fair value changes on warrant liabilities Disclosure of intangible assets amortization expenses explanatory. Amortization research and development expense. Written off of intangible asset. Disclosure of other receivables explanatory. Advance Cancer Centre Pte Ltd [member] CytoMed Therapeutics (Malaysia) Sdn Bhd [member] LongevityBank Pte Ltd [member] IPSC Depository Sdn Bhd [member] Puricell Lab Pte Ltd [member] Accumulated noncontrolling interests. Fair value adjustments of noncontrolling interests. Proceeds from cash receipts from repayment of advances and loans made to related parties. Offering expenses of attributable to the issuance of the new shares. Later than six month and not later than twelve months [member] Overtime [member] Hiring incentive and training programme [member] At A Point In Time [member] Market readiness assistance grant [member] Others [member] Financial asset [member] Financials liabilities [member] Other short term benefits [member] Unused tax losses for deferred tax asset. Defined contribution plans [member] Directors [member] Other key management personnel [member] Later than one years and not later than five years [member] Unquoted equity instruments. Financial assets at FVOCI [member] Share based compensation [member] Private blood banking expenses. Proceeds from dilution of interest in subsidiary. Description of diluted equity interest percentage. Technical [member] Currency realignment. Aggregate offering price. Loan receivable. Increase decrease in warrant liability. Fair value on warrant liabilities at inception date. 2023 Equity Incentive Plan [Member] ATM Sales Agreement [Member] Loss allocated to non-controlling interest. Profit loss on non-controlling interests. Current assets [Default Label] Trade and other non-current receivables Non-current assets [Default Label] Assets Current liabilities [Default Label] Non-current liabilities [Default Label] Liabilities Other reserves Equity attributable to owners of parent Equity and liabilities PrivateBloodBankingExpenses Research and development expense Depreciation, property, plant and equipment AmortizationOfIntangibleAsset Employee benefits expense Finance costs Other expense, by function Tax expense (income) ProfitLossAttributableToNoncontrollingInterest Comprehensive income, attributable to owners of parent Comprehensive income, attributable to non-controlling interests Weighted average number of ordinary shares used in calculating basic earnings per share Weighted average number of ordinary shares used in calculating diluted earnings per share Gains (losses) on disposals of investments Adjustments for share-based payments FairValueOnWarrantLiabilitiesAtInceptionDate AdjustmentsForUnrealizedCurrencyTranslationGainsLosses Adjustments to reconcile profit (loss) other than changes in working capital Adjustments for decrease (increase) in trade and other receivables Adjustments for increase (decrease) in contract liabilities Adjustments for increase (decrease) in trade accounts payable Cash flows from (used in) operations Income taxes paid (refund), classified as operating activities Cash advances and loans made to related parties Purchase of property, plant and equipment, classified as investing activities Purchase of intangible assets, classified as investing activities PaymentToFairValueThroughOtherComprehensiveIncomeInvestment Interest received, classified as investing activities Cash repayments of advances and loans from related parties Repayments of borrowings, classified as financing activities Payments of lease liabilities, classified as financing activities Interest paid, classified as financing activities Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Cash and cash equivalents [Default Label] Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Description of accounting policy for investment in associates [text block] Description of accounting policy for property, plant and equipment [text block] Description of accounting policy for intangible assets other than goodwill [text block] Description of accounting policy for trade and other payables [text block] Description of accounting policy for borrowing costs [text block] Description of accounting policy for research and development expense [text block] Description of accounting policy for issued capital [text block] Description of accounting policy for determining components of cash and cash equivalents [text block] Other current receivables Trade and other receivables [Default Label] InvestmentsInSubsidiariesJointVenturesAndAssociatesCurrencyRealignment Name of associate Principal place of business of associate Country of incorporation of associate Disposals, property, plant and equipment Intangible assets and goodwill Increase (decrease) through net exchange differences, intangible assets other than goodwill Additions other than through business combinations, intangible assets other than goodwill AmortizationResearchAndDevelopmentExpense Non-current financial assets Trade and other payables [Default Label] Secured bank loans received Lease liabilities [Default Label] CurrencyRealignmentOnLeaseLiabilities PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities NumberOfWarrantsOutstanding Weighted average exercise price of share options exercisable in share-based payment arrangement Exercise price of outstanding share options Number of shares outstanding Issuance of ordinary shares [Default Label] CurrencyRealignment Revenue from contracts with customers FairValueLossGainOnConvertibleLoans WrittenOffOfIntangibleAsset Losses on disposals of property, plant and equipment Other expenses, by nature Short-term employee benefits expense EmployeeBenefitsUnderResearchExpenses OfferingExpenses OtherProfessionalFeesExpense Utilities expense OtherExpense Tax effect of revenues exempt from taxation Unused tax losses for which no deferred tax asset recognised AdditionToUnusedTaxLosses UnabsorbedTaxLossesForCapitalAllowance AdditionToUnabsorbedCapitalAllowance OverprovisionInRespectOfPriorYearsUnabsorbedCapitalAllowance UnutilizedTaxLossesAndUnabsorbedCapitalAllowanceNet Current warrant liability Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts Liabilities arising from financing activities Interest expense on borrowings CapitalizationOfNewLeasesDuringYear IncreaseDecreaseConversionOfConvertibleUnits Increase (decrease) through changes in fair values, liabilities arising from financing activities Transfers of research and development from entity, related party transactions Amount incurred by entity for provision of key management personnel services provided by separate management entity